Tianda Pharmaceuticals (HKSE:00455) Other Net Income (Loss) : HK$0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Tianda Pharmaceuticals Other Net Income (Loss)?

Tianda Pharmaceuticals's Other Net Income (Loss) for the six months ended in Dec. 2023 was HK$0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.0 Mil.

Tianda Pharmaceuticals's quarterly Other Net Income (Loss) stayed the same from Sep. 2022 (HK$0.0 Mil) to Jun. 2023 (HK$0.0 Mil) but then increased from Jun. 2023 (HK$0.0 Mil) to Dec. 2023 (HK$0.0 Mil).

Tianda Pharmaceuticals's annual Other Net Income (Loss) stayed the same from Mar. 2021 (HK$0.0 Mil) to Mar. 2022 (HK$0.0 Mil) but then declined from Mar. 2022 (HK$0.0 Mil) to Dec. 2023 (HK$-0.0 Mil).

Tianda Pharmaceuticals Other Net Income (Loss) Historical Data

The historical data trend for Tianda Pharmaceuticals's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianda Pharmaceuticals Other Net Income (Loss) Chart

Tianda Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

Tianda Pharmaceuticals Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Jun23	Dec23
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Tianda Pharmaceuticals Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

Tianda Pharmaceuticals Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Tianda Pharmaceuticals's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Tianda Pharmaceuticals (HKSE:00455) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianda Pharmaceuticals Ltd (HKSE:00455) » Definitions » Other Net Income (Loss)

Traded in Other Exchanges

N/A

Address

CITIC Tower, No. 1 Tim Mei Avenue, Suites 2405-2410, 24th Floor, Central, Hong Kong, HKG

Website

https://www.tiandapharma.com

Tianda Pharmaceuticals Ltd is engaged in R&D, manufactures and sales of pharmaceutical, biotechnology and healthcare products. The group also engages in R&D of Chinese medicine and manufacture and sales of Chinese medicine products, and the provision of Chinese medical services. Its operating segments include Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives majority of the revenue from Pharmaceuticals and medical technologies business.

Executives

Tianda Group Limited	2101 Beneficial owner
Fang Wen Quan	2201 Interest of corporation controlled by you

Tianda Pharmaceuticals (HKSE:00455) Headlines

No Headlines